Lifecore Biomedical, Inc. (LFCR) |
|
7.58 -0.34 (-4.29%)
|
09-27 16:00 |
|
Open: |
7.95 |
Pre. Close: |
7.92 |
|
High:
|
8 |
Low:
|
7.53 |
|
Volume:
|
221,532 |
Market Cap:
|
224(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 4:20:32 PM |
|
Short-term rate:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
|
Mid-term rate:
|
|
| Target: |
Six months: 9.84 One year: 10.61 |
| Support: |
Support1: 7.36 Support2: 6.13 |
| Resistance: |
Resistance1: 8.43 Resistance2: 9.09 |
| Pivot: |
7.87 |
| Moving Average: |
MA(5): 7.89 MA(20): 7.93
MA(100): 8.46  MA(250): 7.28 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.4 |
| Stochastic oscillator: |
%K(14,3): 48.6 %D(3): 57.1 |
| RSI: |
RSI(14): 35.1 |
| 52-week: |
High: 11.46 Low: 1.51 |
| Average Vol(K): |
3-Month: 249 (K) 10-Days: 171 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ LFCR ] has closed above bottom band by 20.0%. Bollinger Bands are 52.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
8.01 - 8.07 |
8.07 - 8.12 |
|
Low:
|
7.4 - 7.47 |
7.47 - 7.52 |
|
Close:
|
7.49 - 7.6 |
7.6 - 7.67 |
|
Company Description |
|
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California. |
Headline News |
Fri, 22 Sep 2023
Prelude Capital Management LLC Invests $80000 in Lifecore ... - MarketBeat
Sun, 10 Sep 2023
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims ... - GlobeNewswire
Fri, 01 Sep 2023
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Q4 2023 Earnings Call Transcript - Yahoo Finance
Thu, 31 Aug 2023
North American Morning Briefing : PCE Inflation -2- - 2023-08-31 - Marketscreener.com
Thu, 31 Aug 2023
Healthcare Stocks Moving Up and Down Thursday: ADTX, ACER, SQL, BDRX, OKYO, LFCR, EYPT, ALXO - InvestorsObserver
Fri, 11 Aug 2023
Do You Think Lifecore Biomedical (LFCR) Will Get Sold for a Healthy Premium? - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
30 (M) |
| Shares Float |
17 (M) |
|
% Held by Insiders
|
2.7 (%) |
|
% Held by Institutions
|
77.7 (%) |
|
Shares Short
|
1,800 (K) |
|
Shares Short P.Month
|
1,680 (K) |
Stock Financials |
|
EPS
|
-2.25 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-0.06 |
|
Profit Margin (%)
|
-99 |
|
Operating Margin (%)
|
-23.3 |
|
Return on Assets (ttm)
|
-5.5 |
|
Return on Equity (ttm)
|
-95 |
|
Qtrly Rev. Growth
|
-67 |
|
Gross Profit (p.s.)
|
0.92 |
|
Sales Per Share
|
3.49 |
|
EBITDA (p.s.)
|
-0.47 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-34 (M) |
|
Levered Free Cash Flow
|
15 (M) |
Stock Valuations |
|
PE Ratio
|
-3.37 |
|
PEG Ratio
|
-8.2 |
|
Price to Book value
|
-126.34 |
|
Price to Sales
|
2.16 |
|
Price to Cash Flow
|
-6.5 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
